Stockholm-based Eyedentity secures €1.3 million to detect deadly eye cancer earlier with AI

According to EU-Startups, homeFundingStockholm-based Eyedentity secures €1.3 million to detect deadly eye cancer earlier with… HomeFundingStockholm-based Eyedentity secures €1.3 million to detect deadly eye cancer earlier with…FundingSweden Startups Stockholm-based Eyedentity secures €1.3 million to detect deadly eye cancer earlier with AI By David Cendon Garcia August 21, 2026 Share FacebookTwitterWhatsAppLinkedin MedTech startup Eyedentity has closed its first over3 million (SEK 15 million) to support regulatory approval, further product development and the expansion of Eyedentity’s AI-powered diagnostics platform into opticians, eye clinics and hospitals.The round was led by Norrsken Launcher, with participation from the Karolinska Institutet Innovation and a group of angel investors.Key players involved: Goldman Sachs Asset Management, Partners Group This development has significant implications for the industry, potentially influencing competitive dynamics, investment patterns, and strategic priorities across the sector. EU-Startups has seen notable similar rounds, including: €13.6 million for Nijmegen-based ScreenPoint Medical’s AI-powered breast cancer imaging technology €2.8 million for Swiss image-analysis startup Moonlight AI €16.6 million for Cambridge-based respiratory diagnostics company TidalSense €10 million for French-Belgian neurodiagnostics startup neuroClues €24 million in financing for Eindhoven-based ShanX Medtech A same-country comparator includes Lund-based MedVasc, who raised €2.2 million this year to advance their anesthesia catheter towards US approval. Market ImplicationsForward-Looking IndicatorsContinued consolidation expected in the sectorIncreasing focus on digital transformation and innovationGrowing importance of ESG considerations Expert Commentary Looking AheadFor complete details on this development, refer to the original report from EU-Startups. Frequently Asked Questions